NovoCure

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NovoCure and other ETFs, options, and stocks.

About NVCR

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. 

CEO
Frank Leonard
CEOFrank Leonard
Employees
1,488
Employees1,488
Headquarters
St. Helier, Jersey
HeadquartersSt. Helier, Jersey
Founded
2000
Founded2000
Employees
1,488
Employees1,488

NVCR Key Statistics

Market cap
1.53B
Market cap1.53B
Price-Earnings ratio
-8.48
Price-Earnings ratio-8.48
Dividend yield
Dividend yield
Average volume
3.04M
Average volume3.04M
High today
$14.38
High today$14.38
Low today
$13.26
Low today$13.26
Open price
$13.49
Open price$13.49
Volume
2.58M
Volume2.58M
52 Week high
$21.55
52 Week high$21.55
52 Week low
$9.82
52 Week low$9.82

Stock Snapshot

As of today, NovoCure(NVCR) shares are valued at $13.45. The company's market cap stands at 1.53B, with a P/E ratio of -8.48.

During the trading session on 2026-03-02, NovoCure(NVCR) shares reached a daily high of $14.38 and a low of $13.26. At a current price of $13.45, the stock is +1.4% higher than the low and still -6.5% under the high.

Trading activity shows a volume of 2.58M, compared to an average daily volume of 3.04M.

Over the past 52 weeks, NovoCure(NVCR) stock has traded between a high of $21.55 and a low of $9.82.

Over the past 52 weeks, NovoCure(NVCR) stock has traded between a high of $21.55 and a low of $9.82.

NVCR News

Simply Wall St 2d
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile

NovoCure (NasdaqGS:NVCR) received FDA approval for Optune Pax in locally advanced pancreatic cancer and has started commercial launch. The approval extends the...

NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile
Nasdaq 4d
NovoCure Q4 Loss Declines

(RTTNews) - NovoCure (NVCR) released Loss for fourth quarter of -$24.499 million The company's bottom line totaled -$24.499 million, or -$0.22 per share. This...

NovoCure Q4 Loss Declines
TipRanks 4d
Novocure reports Q4 EPS (22c), consensus (41c)

Reports Q4 revenue $174.35M, consensus $173.36M. “In 2025, a record number of patients received treatment with Novocure’s (NVCR) Tumor Treating Fields therapy,...

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%

More NVCR News

TipRanks 5d
Novocure says CMS rescinds revocation of billing privileges

Novocure (NVCR) disclosed that on February 24, it received a letter from Centers for Medicare and Medicaid Services rescinding the revocation of billing privile...

TipRanks 5d
NovoCure Has Medicare Billing Privileges Reinstated by CMS

NovoCure ( (NVCR) ) just unveiled an announcement. On February 2, 2026, Novocure Inc. disclosed that the Centers for Medicare & Medicaid Services had revoked i...

Nasdaq 6d
Interesting NVCR Put And Call Options For April 17th

Investors in NovoCure Ltd (Symbol: NVCR) saw new options become available this week, for the April 17th expiration. At Stock Options Channel , our YieldBoost fo...

Interesting NVCR Put And Call Options For April 17th

People also own

Based on the portfolios of people who own NVCR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.